Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 71 publications
Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia.
Journal: British journal of haematology
Published: August 28, 2025
Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mutated pancreatic cancer.
Journal: Experimental hematology & oncology
Published: January 15, 2025
Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience.
Journal: Annals of hematology
Published: September 08, 2024
HyperCVAD versus pegaspargase-containing regimens for Hispanic adults with newly diagnosed B-cell acute lymphoblastic leukemia.
Journal: European journal of haematology
Published: August 17, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
Journal: Blood cancer journal
Published: March 30, 2023
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses.
Journal: Research square
Published: March 03, 2023
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses.
Journal: Nature cancer
Published: January 26, 2023
Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting.
Journal: Clinical lymphoma, myeloma & leukemia
Published: October 28, 2022
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
Journal: American journal of hematology
Published: October 21, 2022
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 18, 2022
Last Updated: 09/26/2026